A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension

Trial Profile

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms CATALYST
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 1 May 2018 to 31 Oct 2018.
    • 14 Nov 2016 According to Reata Pharmaceuticals media release, out of of 22 patients with pulmonary hypertension caused by interstitial lung diseases in LARIAT trial, 19 meet the final inclusion criteria of this trial.
    • 14 Nov 2016 According to a Reata Pharmaceuticals media release, data from this trial expected during the first half of 2018. Data from CATALYST and LARIAT trials will be utilized for a New Drug Application review of the safety profile of the drug.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top